Tuesday 28 March 2023

Are we close to a pill to combat covid-19?

Paying the bills


Every 11 minutes there is a crime in Costa Rica

QCOSTARICA - Every 11 minutes and 46 seconds, a...

Central Bank went too far, says José Álvaro Jenkins, president of Uccaep

QCOSTARICA - The measures taken by the Banco Central...

Vehicle restrictions of San Jose suspended for Semana Santa

QCOSTARICA - Driving in and around the inner core...

Uncovering the secret religious and spiritual lives of sex workers

Q REPORTS (The Conversation) Tanya* is telling me just...

Costa Rica strengthens trade relations with the Netherlands

QCOSTARICA - Within the framework of President Rodrigo Chaves'...

Family remittances in Nicaragua rose 63.2% in January and February

Q24N (EFE) Nicaraguans received US$647.6 million dollars between January...

Medical devices, pineapples, and bananas were the most exported products from Costa Rica in 2022

QCOSTARICA - Medical devices and fresh tropical pineapples were...

Dollar Exchange

¢542.43 Buy

¢547.51 Sell

25 March 2023 - At The Banks - BCCR

Paying the bills


Will pharmacies soon have covid-19 drugs on their shelves? After vaccines, drug companies are now in the race to develop a treatment that can be taken at home with a glass of water as soon as symptoms appear.

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on May 17, 2021. Merck & Co Inc/Handout via REUTERS

Because although prevention is better than cure, as the saying goes, knowing how to cure is still crucial.

What is an antiviral?

There are already antivirals for other viruses, such as HIV, which causes AIDS, and the flu. At the beginning of the pandemic, funding and research focused on the development of vaccines, which partly explains the delay in the development of antivirals against the coronavirus.

- Advertisement -

“Viruses are small machines that need certain components to replicate,” explains Daria Hazuda, a biochemist who has been working on these treatments for years.

“Antivirals are usually small chemical molecules, developed to interfere with this machinery,” she says. “They introduce a mutation into the virus, and when this happens multiple times, these mutations reduce the virus’s ability to replicate,” she adds.

By curbing the disease, severe cases, hospitalizations, and deaths can be avoided.

The ongoing projects

There are currently two relatively advanced projects, tested on more than 1,000 people.

The first is that of the American pharmaceutical company Merck, in association with the biotechnology company Ridgeback Biotherapeutics. The product is called Molnupiravir.

Developed initially to treat the flu, it has been modified so that it can be taken in pill form, to be taken twice a day for five days.

- Advertisement -

The treatment has been very well tolerated by the few hundred people who have already received it. Analyzes of several dozen of them showed that the virus was no longer detectable after five days for all those treated with Molnupiravir, but it was still detectable in 26% of the placebo group (test product with no medicinal value).

Results of trials in another 1,450 adults are expected in October.

The second project is from the Swiss pharmaceutical company Roche, in collaboration with the American company Atea Pharmaceuticals.

Called AT-527, the treatment is being tested in about 1,400 participants in Europe and Japan, this time starting at the age of 12.

- Advertisement -

“We hope to seek regulatory approval by the end of the year and launch the drug in 2022,” said Atea CEO Jean-Pierre Sommadossi.

A third, less advanced project is being developed by Pfizer. Unlike the others, the treatment called PF-07321332 was developed specifically against SARS-CoV-2, the virus that causes covid-19. It is being tested in about 60 adults, with results expected by the end of June.

A challenge: take it quickly

Both Merck and Roche require that the drug be taken within five days of the onset of symptoms.

This is because the virus replicates more during the first week.

“The sooner you treat with an antiviral, the better the outcome,” says Daria Hazuda, who leads Merck’s drug research.

This explains the relative failure of Remdesivir, the only antiviral against COVID-19 approved so far. Produced by the American laboratory Gilead Sciences, it must be administered intravenously in the hospital.

This means that patients are too advanced in the disease to get any real benefit from it.

Once the pills are available, the main challenge will be to diagnose patients very early.

Benefits: prevention and variants

But these antivirals should also be able to be used for prevention: for example, when one member of a family becomes infected, the others can take treatment to avoid developing the disease.

Finally, experts are confident in the ability of antivirals to remain effective against variants, as well as against other coronaviruses, including some still unknown.

- Advertisement -
Paying the bills
Avatar photo
"Rico" is the crazy mind behind the Q media websites, a series of online magazines where everything is Q! In these times of new normal, stay at home. Stay safe. Stay healthy.

Related Articles

The number of cases due to Covid-19 drops after several weeks of increases

QCOSTARICA - It seems that the cases of Covid-19 are beginning...

Costa Rica: three years since the first case of Covid-19

QCOSTARICA - On Monday, March 6, like any other Monday, but...

Subscribe to our stories

To be updated with all the latest news, offers and special announcements.